You are here: Home » News-ANI » Science
Business Standard

Scientists discover sweet spot of activity in immune system, key to fight cancer

ANI  |  Washington D.C. [USA] 

Scientists at have shown how stimulating a specific location on the surface of immune cells can be targeted with to help in their fight against

The new work concerns a receptor called CD40 found on the surface of certain immune cells which regulates their activity. The CD40 receptors are normally dispersed over the surface of resting immune cells, but must be concentrated and clustered into highly organised complexes in order to trigger an immune response against Scientists believe that very precise clustering is required to trigger an activation signal to 'kick-start' the immune cells as they fight diseases, including

The use of the body's own to find and kill cells is rapidly changing the way the is managed and treated. displays unique markers that can be recognised by the but frequently prevents the immune system's attack by putting the immune cells into a state of exhaustion.

A new family of immune-boosting drugs, many of which have origins in laboratories, are able to reverse the cells ability to exhaust the immune cells and kick starts them. Even though results in clinical trials are very promising, with many patients being cured, it does not work for all patients. However the scientists believe better understanding of how these immune-stimulating work will improve results for more patients.

The pre-clinical study was carried out by scientists from the University's and based at the new Centre for Immunology, alongside researchers in Biological Sciences and the

The study also found that the ability of drugs, which bind to the CD40 protein, to cluster the immune cell's receptors was a key requirement for the immune cell to "wake up" and fight the

Martin Glennie, on the paper, said: "Understanding the complex dynamics between where and how an drug engages an immune cell is key to designing more efficient treatments.

"It is the combination of the location of CD40, which seems to be a real sweet spot of activity, along with the ability to cluster the immune cell's receptors that gives such a potent response, one that we hope will be translated into the clinic to benefit patients," he added.

Dr said, "This work underlines how teams of scientists, with expertise in different aspects of cellular and molecular biology, structural determination and modelling are needed to crack the difficult problems involved in engineering the next generation of drugs."

The study has been published in Cell.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, April 17 2018. 19:25 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU